 STUDY OF PEMBROLIZUMAB MK-3475 VERSUS INVESTIGATORS CHOICE STANDARD THERAPY FOR PARTICIPANTS WITH ADVANCED ESOPHAGEALESOPHAGOGASTRIC JUNCTION CARCINOMA THAT PROGRESSED AFTER FIRST-LINE THERAPY MK-3475-181KEYNOTE-181: 